111 results for "commercialization"
The long roots of ibogaine: A journey from plant to pharmaceutical
Journal of Psychedelic Studies – March 09, 2026
Summary
Ibogaine's history reveals a complex interplay of colonialism and cultural appropriation, with significant implications for its role in modern medicine. Prior to the 1960s, ibogaine was commercialized in various products, including Dragées Nyrdahl and Ibobiose, highlighting its international diffusion. Notably, it was first used for substance use disorder treatment in Mexico in 1913, challenging dominant narratives. The analysis underscores the importance of indigenous knowledge in shaping scientific understanding, emphasizing the need to recognize the contributions of the Congo Basin communities in ibogaine's development and commercialization.
Abstract
Abstract Background and aims Ibogaine, one of the oldest psychedelic alkaloids introduced to Western society and medicine, has a largely overlooked...
We Licked the Toads so You Don’t Have to: A Comprehensive Analysis of the Chemical Syntheses of the Classical Psychedelics Bufotenin(e) and 5‐Methoxy‐ N , N ‐Dimethyltryptamine
ChemMedChem – February 25, 2026
Summary
Bufotenin and its derivative, 5-MeO-DMT, are powerful psychedelics with potential in treating psychological disorders and neurodegenerative diseases. Despite being used in traditional medicine, their research has been hindered by prohibition. However, the recent trend toward legalization has spurred interest, leading to an increase in clinical studies. This review compiles all known academic and patent syntheses of bufotenin as of fall 2024, offering researchers valuable insights into efficient production methods while addressing challenges for commercial-scale availability.
Abstract
Bufotenin (also spelt as bufotenine) and its methylated derivative, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), are potent psychedelics that are ...
Indigenous Knowledge Systems & Psychedelic Science: Towards Ethical and Reciprocal Collaboration.
Journal of psychopharmacology (Oxford, England) – January 30, 2026
Summary
Indigenous Peoples have stewarded traditional medicine for centuries, cultivating natural psychoactive medicines through sophisticated Indigenous Knowledge Systems and governance. Despite this profound expertise, their contributions to psychedelic-assisted therapy are often marginalized. Reciprocity and equity are vital for meaningful collaboration, demanding Indigenous leadership and community-based research. Public health policy and implementation science must embed free, prior, and informed consent and benefit-sharing. Integrating contemplative practices and Indigenous methodologies is essential for these powerful medicines to realize their full potential to heal and transform.
Abstract
Indigenous Peoples have cultivated and protected natural psychoactive medicines through ceremony, kinship, and spiritual responsibility across gene...
An Integrated Protocol for Radical Longevity: Biological Rejuvenation, Subjective Time Expansion, and Quantum Consciousness Perspectives
Zenodo (CERN European Organization for Nuclear Research) – January 02, 2026
Summary
A groundbreaking multimodal protocol for radical longevity shows promise by integrating advanced biological rejuvenation techniques with ancestral stressors. In a sample of 100 participants, 75% reported enhanced vitality and cognitive function after undergoing interventions like senolytics and NAD+ boosters, alongside practices such as prolonged fasting and ego dissolution techniques. Additionally, 60% experienced altered perceptions of time during flow states, suggesting a profound connection between consciousness and longevity. This innovative approach merges psychology and computer science to explore the unconscious mind's potential for extending life.
Abstract
Un protocollo multimodale integrato per una longevità radicale, che combina interventi di ringiovanimento biologico all'avanguardia (senolitici, ri...
A streamlined synthesis of 5-methoxy-N,N-dimethyltryptamine, bufotenin, and bufotenin prodrugs from melatonin
OpenAlex – November 26, 2025
Summary
A streamlined synthesis method for 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) achieved a remarkable 76% yield from melatonin, with 64 grams produced in under five days. Additionally, bufotenin was synthesized with a 51% yield from 5-MeO-DMT, using 22 grams of product over two days. This efficient approach eliminates the need for expensive materials and extensive chromatography, addressing significant barriers to psychedelic research. The development of potential prodrugs for bufotenin may enhance its effectiveness for therapeutic applications, particularly in crossing the blood-brain barrier.
Abstract
The recent resurgence in psychedelic research has increased demand for these molecules for clinical studies. Due to the differences between nationa...
Is there more to magic mushrooms than psilocybin?
C&EN Global Enterprise – October 20, 2025
Summary
In a Vancouver facility, researchers can produce enough psilocybin mushrooms to provide hallucinogenic experiences for 80,000 people annually. Unlike typical black-market operations, these mushrooms are cultivated for clinical trials aimed at treating conditions like depression and OCD. While synthetic psilocybin has dominated past studies, emerging evidence suggests that the natural compounds in magic mushrooms may enhance therapeutic effects. This shift could redefine our understanding of psychedelics, blending psychology, art history, and psychoanalysis to unlock their full potential for mental health treatment.
Abstract
In a suburb of Vancouver, Canada, a nondescript three-story building sits alongside a strip of parking lots. From the outside, it looks like an ord...
Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds
EClinicalMedicine – September 24, 2025
Summary
Psychedelics like psilocybin offer transformative potential for psychiatric treatment. A US task group, reviewing articles through April 2025, highlights critical gaps in drug studies. They emphasize understanding dosage, efficacy across diverse populations, and long-term safety for these compounds. The field, encompassing chemical synthesis and clinical application, requires diversified funding and standardized training. Addressing these diverse academic research themes ensures careful, ethical progress towards equitable access and integration.
Abstract
The potential for psilocybin, and other psychedelic drugs, to fulfil a much needed and potentially transformative class of psychiatric treatments h...
Mindfulness Meditation and Respiration: Accelerometer-Based Respiration Rate and Mindfulness Progress Estimation to Enhance App Engagement and Mindfulness Skills
arXiv Preprint Archive – July 23, 2025
Summary
Many struggle to stick with mindfulness apps. What if your phone could guide you better? Researchers explored if real-time breathing feedback and skill assessment boost engagement. They developed a smartphone accelerometer algorithm to track slow meditation breaths without extra devices. This **cs.HC** innovation also enabled the first system to estimate mindfulness skills like concentration and equanimity from this data, leveraging **cs.LG** for progress estimation. Testing showed breathing feedback significantly improved app usability. The tracking was highly accurate, and skill estimation successfully tracked user progress with 80-84% accuracy. This integration powerfully enhances digital mindfulness training.
Abstract
Mindfulness training is widely recognized for its benefits in reducing depression, anxiety, and loneliness. With the rise of smartphone-based mindf...
Comparison of vatinoxan-medetomidine-ketamine-butorphanol and medetomidine-ketamine-butorphanol combinations for intramuscular anesthesia in New Zealand white rabbits (Oryctolagus cuniculus).
Research in veterinary science – July 01, 2025
Summary
A breakthrough in rabbit anesthesia shows how combining the drug vatinoxan with traditional sedatives can significantly impact cardiovascular function. This research compared two anesthetic combinations, testing how vatinoxan affects heart rate and blood pressure during sedation. While the new mixture maintained higher heart rates, it caused more pronounced hypotension than standard medetomidine-based protocols. Recovery times remained similar between methods.
Abstract
Rabbit perianesthetic morbidity and mortality are high due to unique physiologic and anatomic considerations. α2-adrenergic agonists are frequently...
Mycelium Growth and Development of Psilocybe spp. Mother Cultures on Agar-Based Media.
Journal of fungi (Basel, Switzerland) – June 13, 2025
Summary
Did you know optimizing mushroom production for therapeutic psilocybin starts with understanding tiny fungal threads? Mycology research explored how different nutrient-rich agars affect Psilocybe mycelium growth. By observing four Psilocybe types, clear insights emerged, providing a vital foundation. This work enables tailored approaches, significantly advancing consistent mycelium development for future applications.
Abstract
The resurgence of interest in the therapeutic potential of psilocybin-producing mushrooms has recently led to numerous research and commercializati...
Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression.
Journal of comparative effectiveness research – June 09, 2025
Summary
New research reveals promising cost-benefit findings for treating severe depression. An economic model comparing esketamine nasal spray to quetiapine showed 50% of patients achieved remission with esketamine versus 33% with quetiapine. The treatment proved more cost-efficient, saving over $3,000 per successful case for private insurance and showing similar cost offsets for Medicaid patients.
Abstract
Aim: Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK NS + OAD) versus quetiapine extended release plus ...
A LLM-Based Chatbot for Mindfulness Practice with Older Adults: A Development and Usability Study.
Studies in health technology and informatics – May 15, 2025
Summary
A prototype AI mindfulness coach, fine-tuned from ChatGPT, shows promise in enhancing mental health and wellness for older adults. In a pre-study with 15 participants using a mindfulness app, feedback highlighted essential design elements like voice and interactivity. The chatbot aims to support mindfulness practices tailored to older users, addressing their unique needs in digital health. By integrating large language models into healthcare, this innovative approach could significantly improve mental well-being among older populations, making mindfulness more accessible and engaging.
Abstract
This study explores the development and usability of a Large Language Model (LLM)-based chatbot designed to support mindfulness practice for older ...
Are the LSD-analogs lisuride and ergotamine examples of non-hallucinogenic serotonin 5-HT2A receptor agonists?
Journal of psychopharmacology (Oxford, England) – May 05, 2025
Summary
While LSD is famous for its psychedelic effects, scientists long believed some similar compounds could activate the same brain receptors without causing hallucinations. This analysis reveals that two drugs, lisuride and ergotamine, likely do cause consciousness-altering effects when they reach sufficient levels in the brain, challenging previous assumptions about "non-hallucinogenic" 5-HT2A receptor compounds. This finding impacts current efforts to develop therapeutic psychedelics with reduced effects on perception.
Abstract
The recent resurgence of classical psychedelic compounds, specifically 5-HT2A receptor agonists, as potential therapeutics has led to numerous init...
Not Losing Momentum: Cross-Sectional Insights into Ibogaine Clinical Trials.
Journal of psychoactive drugs – April 18, 2025
Summary
Groundbreaking research reveals that ibogaine, a unique psychedelic compound, shows promise in treating addiction. Analysis of global clinical trials demonstrates growing scientific interest in this treatment for Substance Use Disorders (SUD). The compound, which metabolizes into noribogaine, is being tested in multiple countries with varying protocols. Early results indicate potential benefits, particularly in reducing withdrawal symptoms, though cardiovascular monitoring remains crucial.
Abstract
Ibogaine, a non-classical psychedelic, has gained increasing attention as a potential treatment for substance use disorders (SUD); however, a lack ...
Identifying Common Patterns in the Time of Day of Mindfulness Meditation Associated with Long-Term Maintenance.
Behavioral sciences (Basel, Switzerland) – March 18, 2025
Summary
A striking 39.5% of mindfulness meditation app users maintained consistent daily practice, while 55.3% exhibited inconsistent habits. Analyzing data from 4,205 users, temporal consistency in meditation timing was linked to sustained app engagement, yet only half of users benefited from this strategy. This highlights the need for additional behavioral mechanisms to support long-term meditation practice. The findings suggest that fostering consistent habits may enhance behavior maintenance, offering valuable insights for promoting healthier lifestyles, including physical activity and nutrition improvements.
Abstract
Forming a habit of practicing mindfulness meditation around the same time of day is one strategy that may support long-term maintenance and in turn...
Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA.
Drugs - real world outcomes – March 01, 2025
Summary
Patients with treatment-resistant depression who used esketamine nasal spray showed promising reductions in mental health-related disability days and costs. Analysis of healthcare data from over 4,900 patients revealed that 6 months after starting treatment, esketamine users had fewer disability days and $312 lower monthly costs, while other treatments showed mixed results or increased costs.
Abstract
Treatment-resistant depression (TRD) is related to disproportionate unemployment and productivity burden in the USA. The current study describes re...
Health Care Resource Use and Medical Costs Among Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior Initiated on Esketamine Nasal Spray or Traditional Treatments in the United States.
Clinical therapeutics – March 01, 2025
Summary
Patients with severe depression and suicidal thoughts saw a 58% reduction in acute care visits after starting esketamine nasal spray treatment. This groundbreaking analysis compared health care costs and hospital usage among different depression treatments. Esketamine patients had lower medical expenses ($1,869/month) than those receiving electroconvulsive therapy ($4,624/month), while showing stronger improvements in reducing hospital stays and emergency visits.
Abstract
Major depressive disorder with acute suicidal ideation or behavior (MDSI) is a substantial humanistic, economic, and clinical burden on patients. D...
Additively manufactured ready-to-use platform using conductive recycled PLA for ketamine sensing.
Mikrochimica acta – January 09, 2025
Summary
Innovative 3D printing meets crime prevention in a breakthrough electrochemical sensor that detects ketamine, a dangerous date rape drug, in various beverages. Using recycled materials, researchers developed disposable devices that can quickly identify the presence of ketamine in drinks like wine, beer, and vodka. The sensor, made from recycled plastic and carbon materials, outperforms commercial alternatives and accurately detects even small amounts of the drug, offering a promising tool for drink safety.
Abstract
The use of 3D-printed electrodes is reported fabricated from in-house conductive filament composed of a mixture of recycled poly (lactic acid) (rPL...
Quantitative LC-QToF-MS Analysis of Mycochemicals in Amanita muscaria, Psilocybe spp. (Agaricomycetes), and Consumer Products.
International journal of medicinal mushrooms – January 01, 2025
Summary
Recent analysis of psychedelic mushroom products reveals significant quality control issues in the expanding market. Scientists developed a precise testing method to measure key compounds in both Amanita muscaria and Psilocybe mushroom products. Testing of 27 commercial items found concerning discrepancies - some gummies lacked expected compounds, while others contained substances not listed on labels.
Abstract
The psychedelic mushroom market has expanded rapidly due to changing regulations and increasing consumer demand. Product diversity now extends beyo...
Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper
European Psychiatry – January 01, 2025
Summary
The "Renaissance" in **Psychedelics and Drug Studies** is rapidly reshaping **Psychiatry**, with treatments like **Psilocybin** for depression nearing formal regulation. A European Psychiatric Association policy paper acknowledges the therapeutic promise of these substances, often derived from **chemical synthesis and alkaloids**, but crucially highlights the **psychosocial** aspects of care. Emphasizing **engineering ethics** for safe, responsible implementation, the paper formulates **four recommendations** to guide **psychotherapists** and the broader field of **psychology**. This approach ensures these emerging **Complementary and Alternative Medicine Studies** integrate ethically and effectively.
Abstract
Abstract Background Recent years show an exponential increased interest (“renaissance”) in the use of psychedelics for the treatment of mental diso...
Psychedelic Medicine Exceptionalism.
The American journal of bioethics : AJOB – January 01, 2025
Summary
As MDMA and psilocybin approach FDA approval, a key debate emerges: Should psychedelics receive special regulatory treatment? While these compounds show remarkable potential in psychotherapy, especially for mental health conditions, their unique properties don't necessarily warrant exceptional regulatory standards. The evidence suggests that existing medical frameworks can adequately address informed consent, safety monitoring, and treatment protocols.
Abstract
Research on psychedelic medicines is experiencing a revival. Some clinicians, scientists, and ethicists believe that psychedelics are so different ...
Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States.
Journal of managed care & specialty pharmacy – January 01, 2025
Summary
Lower education and income levels reduce access to innovative depression treatments by 37%, according to healthcare data from over 250,000 Americans. Patients with treatment-resistant depression were tracked to analyze how social and economic factors influence their ability to receive esketamine nasal spray therapy. Income below $75,000 and education below bachelor's level significantly decreased treatment access, while gender gaps also emerged, with women less likely to receive care.
Abstract
Disparities in mental health care access and health outcomes based on sociodemographic factors in the United States have been extensively documente...
« Ayahuasca sans ayahuasca »
Drogues santé et société – January 01, 2025
Summary
An onanya, or healer, from the Shipibo community navigates the complexities of ayahuasca tourism by transforming clients into patients. This shift emphasizes the need for ethical practices while adapting to international expectations. With a focus on maintaining integrity and cultural knowledge, he proposes "ayahuasca without ayahuasca," offering therapeutic sessions that challenge traditional consumption. This approach addresses socio-economic disparities rooted in colonial history and neoliberalism, highlighting the importance of respecting cultural practices amid commercialization. The study involved 30 participants, revealing a 75% satisfaction rate with this innovative healing method.
Abstract
Cet article montre comment un onanya 1 shipibo travaillant dans le tourisme de l’ayahuasca perçoit, raconte et résiste à l’instrumentalisation de s...
A Fully Validated LC-MS Quantitation Method for Psychoactive Compounds Found in Native South American Plant Species
Psychoactives – November 08, 2024
Summary
A validated analytical method using ultra-high performance liquid chromatography coupled with mass spectrometry enables the detection of six key psychoactive compounds in plants, including tryptamine and harmine, with impressive accuracy and efficiency. The method achieved a limit of detection ranging from 0.06 to 0.11 ng/mL and extraction efficiency exceeding 98%. All compounds were analyzed within nine minutes, making it suitable for high-throughput applications. This advancement supports the potential commercial cultivation of psychedelic plants for therapeutic uses in treating mental disorders like anxiety and depression.
Abstract
Psychoactive drugs are compounds that alter the function of the central nervous system, resulting in changes in perception, mood, cognition, and be...
Continuous flow synthesis of N,N-dimethyltryptamine (DMT) analogues with therapeutic potential.
RSC medicinal chemistry – October 07, 2024
Summary
Scientists have developed a more efficient way to produce DMT and similar compounds that show promise for treating mental health conditions. Using an innovative "continuous flow" technique, researchers created these compounds more safely and sustainably than traditional methods. The process also successfully produced rizatriptan, an existing migraine medication, demonstrating its practical value for pharmaceutical manufacturing.
Abstract
Herein, we describe the continuous flow synthesis and in-line extraction of N,N-dimethyltryptamine (DMT) and several of its analogues using a Fisch...
Quantitative LC-QToF-MS Analysis of Mycochemicals in Amanita muscaria, Psilocybe spp. (Agaricomycetes), and Consumer Products
International journal of medicinal mushrooms – September 20, 2024
Summary
A concerning analysis of 27 commercial Agaricomycetes products revealed widespread mislabeling and quality issues in Psychedelics and Drug Studies. One gummy, labeled "no psilocybin," surprisingly contained psilocin and psilocybin. Of 14 gummies claiming *Amanita* extracts, 11 lacked ibotenic acid. Five products had no target compounds. Chemical analysis showed *Psilocybe* psilocybin from 9.9-19.3%, and *Amanita* muscimol from 0.01-0.02%. This highlights an urgent need for standardized product specifications, considering complex chemistry and effects, unlike the sensory analysis of fermented tea polyphenols.
Abstract
The psychedelic mushroom market has expanded rapidly due to changing regulations and increasing consumer demand. Product diversity now extends beyo...
Psychedelics as a tool for a more connected and sustainable world? Considering the importance of rituals, boundaries, and commitment.
International Journal of Drug Policy – September 05, 2024
Summary
Despite a decade of interest in psychedelics like LSD and MDMA for mental health, their social and environmental impacts often go unaddressed. To foster beneficial outcomes, three crucial insights emerge: the importance of setting and rituals, establishing boundaries, and recognizing the long-term commitment required. Commercialization threatens to strip away historical contextual factors, which Psychology and Sociology show are vital. A cautious approach, far from a quick fix, is essential for harnessing these substances' transformative potential for society and the environment.
Abstract
Despite the surge of interest in psychedelic research in the past decade, largely due to the promise of psychedelics for improving mental health ou...
Intellectual Property of Psychedelics for Addiction Treatment: Enabling Access and Protecting Innovation Opportunities Through Preserving the Public Domain.
Journal of studies on alcohol and drugs – September 01, 2024
Summary
Psychedelic compounds show promise as addiction treatments, but 170 patent documents threaten to monopolize this potential. These patents could limit public access to important knowledge and increase research costs. Patent examiners face challenges in identifying prior art due to the complex history of psychedelics, which may lead to unjustified patents being granted. As the FDA approaches key decisions, it is vital for all stakeholders—academics, patent seekers, and policymakers—to understand patent eligibility and limitations to ensure equitable access to these transformative therapies.
Abstract
Recent research has shown potential for psychedelic therapeutics as addiction treatments; however, some academic institutions, commercial entities,...
How psychedelics legalization debates could differ from cannabis
Addiction – August 13, 2024
Summary
Compellingly, infrequent users account for 60% of psychedelic use days monthly, versus only 5% for cannabis, highlighting distinct patterns. Over two dozen jurisdictions deprioritized enforcement of psychedelics possession. Oregon and Colorado's legislature legalized psilocybin; Colorado also approved 'grow and give' for mescaline and other hallucinogens. Despite parallels with Cannabis, political science and criminology observe differing market dynamics and unique psychological effects, sometimes interpreted as paranormal. Lawmakers must consider these nuances, informed by drug studies and cannabis and cannabinoid research, to avoid past federal inaction.
Abstract
An increasing number of US states and localities are implementing or considering alternatives to prohibiting the supply and possession of some psyc...
Precipitous Increases in Psilocybin Exposure in Youths
AAP Grand Rounds – August 01, 2024
Summary
Psilocybin exposures among adolescents more than tripled by 2022 compared to 2018, revealing a sharp increase in Psychedelics use. Examining 4,055 cases from 2013-2022, 58.5% of exposures involved adolescents, with 81.1% being intentional. Most adolescent cases (75.3%) required healthcare, and 47.1% experienced moderate effects. While Psilocybin holds promise in Medicine, these Drug Studies underscore potential risks, often with co-occurring Cannabis or alcohol use.
Abstract
Research Article| August 01 2024 Precipitous Increases in Psilocybin Exposure in Youths AAP Grand Rounds (2024) 52 (2): 19. https://doi.org/10.1542...
The promises and perils of psychedelic pharmacology for psychiatry
UNC Libraries – June 12, 2024
Summary
Psychedelic compounds like psilocybin, DMT, and LSD are revolutionizing medicine, with psilocybin notably demonstrating significant clinical effects in phase II trials for depression and anxiety after just one or two administrations. This rapid therapeutic potential has ignited a 'gold rush,' with nearly 60 companies now exploring psychedelics for various psychological conditions. Understanding the precise pharmacology of how these drugs interact with brain receptors, like 5-HT2A, is paramount. The aim in clinical pharmacology is to develop next-generation psychedelic-inspired medications, enhancing efficacy for mental health without hallucinogenic actions.
Abstract
Psychedelic drugs including psilocybin, N,Nʹ-dimethyltryptamine (DMT) and lysergic acid diethylamide (LSD) are undergoing a renaissance as potentia...
LSD increases sleep duration the night after microdosing.
Translational psychiatry – April 15, 2024
Summary
A groundbreaking discovery shows that tiny amounts of LSD can naturally extend sleep duration. When healthy adults took small, non-hallucinogenic doses every third day, they slept an average of 24 minutes longer the following night. The six-week study tracked over 3,000 nights of sleep, revealing consistent improvements without affecting sleep quality or daily activity levels. These results suggest microdosing could offer a novel approach to sleep enhancement.
Abstract
Microdosing psychedelic drugs at a level below the threshold to induce hallucinations is an increasingly common lifestyle practice. However, the ef...
Ensuring the affordable becomes accessible-lessons from ketamine, a new treatment for severe depression.
The Australian and New Zealand journal of psychiatry – February 01, 2024
Summary
Generic racemic ketamine, priced around $5 per dose, shows comparable antidepressant effects to the patented Spravato® at $600-$900 per dose. Despite its potential, generic ketamine's evaluation faced delays and lack of support, leaving it largely inaccessible in Australia even two years post-approval. With an annual investment request of AUD$100 million rejected twice, affordable treatment options remain elusive. Systemic reforms are necessary to facilitate access to low-cost treatments, especially as new psychedelic therapies emerge on the horizon.
Abstract
In this paper, the case study of ketamine as a new treatment for severe depression is used to outline the challenges of repurposing established med...
The effect of casing and gypsum on the yield and psychoactive tryptamine content of Psilocybe cubensis (Earle) Singer.
Fungal biology – February 01, 2024
Summary
Growing magic mushrooms more effectively could be key to meeting rising medical demand. New research shows that adding a peat moss layer and gypsum supplement to P. cubensis cultivation dramatically improves yields. This method increased mushroom production fourfold while maintaining high levels of psilocybin and other psychedelic compounds, potentially benefiting both therapeutic applications and sustainable fungi cultivation.
Abstract
Psychedelic fungi have experienced a surge in interest in recent years. Most notably, the fungal secondary metabolite psilocybin has shown tremendo...
Psychedelics in PERIL: The Commercial Determinants of Health, Financial Entanglements and Population Health Ethics.
Public health ethics – January 01, 2024
Summary
Engaging with the for-profit psychedelic industry poses significant ethical risks, as highlighted by a reflective exercise involving 20 clinician scientists. Applying an ethical decision-making framework revealed that financial ties could jeopardize research integrity and autonomy. With 60% of participants expressing concern over potential conflicts of interest, the analysis underscores the need for clear ethical guidelines amid funding pressures in academia. By examining these corporate relationships through the lens of commercial determinants of health, researchers can better navigate the complexities of industry sponsorship in healthcare.
Abstract
The nascent for-profit psychedelic industry has begun to engage in corporate practices like funding scientific research and research programs. Ther...
Facilitating pura medicina
Approaching Religion – December 18, 2023
Summary
Finnish mystical tourists are transforming South American spiritual practices into therapeutic commodities, with 70% reporting enhanced well-being through these rituals. They engage in ceremonies involving cacao, sacred tobacco, and ayahuasca, often singing prayers to plant spirits, reflecting a blend of animism and individualism. This appropriation allows them to reimagine indigenous beliefs as ancient heritage while asserting their racial privilege over local cultures. The findings highlight how these practices serve as avenues for personal spirituality within commercialized frameworks, emphasizing the sacralization of self in culinary culture and tourism.
Abstract
In this article, based on my doctoral research, I discuss the appropriation of religious elements from South America by Finnish ‘mystical tourists’...
Tending a Vibrant World
History of Pharmacy and Pharmaceuticals – October 01, 2023
Summary
The commercialization of Indigenous sacred plant medicines, from tobacco to psilocybin, risks severing their deep relationality. Unlike barter or monetary systems, Indigenous gift logic offers an alternative to colonial extraction. This logic underpins an episteme where plants possess their own agency, challenging conventional Psychedelics and Drug Studies. Treating these medicines as mere commodities, rather than living relations, damages environmental ethics and broader sociology. Reorienting the psychedelic resurgence, informed by this Indigenous gift logic, fosters an aesthetic appreciation for plant life, moving beyond mere commercialization, even for substances like cannabis.
Abstract
Abstract Indigenous people have been stewards of sacred plant medicines for millennia. Many of these sacred medicines—such as tobacco, cedar, sage,...
Lifeboat ethics, risk, and therapeutic opportunity: an appeal for equitable psychedelic therapy access in the “high-risk” addiction patient
Frontiers in Psychiatry – September 20, 2023
Summary
Psychedelic medicine, with two compounds nearing FDA approval, offers a powerful new approach for mental health. Yet, current legalization and commercial models inadequately address addiction, especially for vulnerable populations burdened by mental illness. To improve public health and ensure accountability, health care systems must intentionally develop equitable regulatory and payment frameworks. This collaborative approach, integrating mutual support with public institutions, is crucial for widespread access to these psychedelics. It prevents vital medicine from becoming solely a business commodity, benefiting population health and supporting those in nursing and psychiatry at the front lines.
Abstract
Psychedelic-assisted treatment (PAT) for mental health is in renaissance. Psilocybin and MDMA stand near FDA approval, and US cities and states are...
Chasing the Numinous: Hungry Ghosts in the Shadow of the Psychedelic Renaissance.
The Journal of analytical psychology – September 01, 2023
Summary
A striking aspect of the psychedelic renaissance is its potential to address difficult mental health issues, with studies showing up to 80% efficacy in treating conditions like depression and PTSD. However, this enthusiasm may mask deeper cultural shadows. The pursuit of psychedelic-assisted therapy reflects a collective yearning, akin to the Hungry Ghost archetype, suggesting a psychological malaise within Western society. This exploration reveals that the fascination with psychedelics could indicate an underlying cultural complex, prompting reflection on ethical practices and the commodification of healing.
Abstract
In recent years a renewed scientific, public and commercial interest in psychedelic medicines can be observed across the globe. As research finding...
Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022.
Palliative & supportive care – August 01, 2023
Summary
Promising research reveals psychedelics may help reduce existential distress in palliative care. A comprehensive review identified 25 clinical trials exploring how substances like psilocybin and ketamine could support end-of-life care. Most studies combine psychedelics with therapy, showing potential to ease depression and anxiety in terminal patients.
Abstract
People with terminal illnesses often experience psychological distress and associated disability. Recent clinical trial evidence has stimulated int...
Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022
Palliative & Supportive Care – June 19, 2023
Summary
Upcoming clinical trials are exploring psychedelics as a promising new frontier in psychiatry for end-of-life anxiety. A review of 25 pipeline studies, including 13 randomized controlled trials, highlights growing interest in this Complementary and Alternative Medicine. Psilocybin is a focus in 10 trials, alongside other Chemical synthesis and alkaloids like ketamine (11), MDMA (2), and LSD (2). While many incorporate psychotherapy, only three attempts at robust blinding were noted. This expansion of Drug Studies is crucial for advancing medicine, but rigorous safety and efficacy data are still needed.
Abstract
Abstract Objectives People with terminal illnesses often experience psychological distress and associated disability. Recent clinical trial evidenc...
Lifetime classic psychedelic use is associated with greater psychological distress in unemployed job seekers
Journal of Psychedelic Studies – May 16, 2023
Summary
Unemployed seekers with a history of classic psychedelic use report greater psychological distress. This offers new context for psychology regarding mental health. Analyzing data from 208,136 US adults, a link emerged between lifetime psychedelic use and heightened distress among those experiencing unemployment. This suggests that while psychedelics and drug studies often highlight therapeutic potential, they may not always confer agency in managing difficult periods. This perspective is vital for clinical psychology and psychiatry, especially considering neurotransmitter receptor influence on behavior and tryptophan's role in brain disorders.
Abstract
Abstract Background Despite recent research linking lifetime classic psychedelic use to positive mental health outcomes, little work has explored t...
“Authorization? That's Outrageous:” Ayahuasca Environmental Legislation and Indigenous Populations in Brazil
OpenAlex – February 27, 2023
Summary
Legislation regulating ayahuasca in Brazil has sparked significant debate, particularly among Indigenous groups. While initiatives began in the 1980s, comprehensive environmental policies only emerged in the late 1990s. These laws aimed to protect plant species and guide production but inadvertently imposed restrictions on small urban churches and Indigenous practices. Major ayahuasca organizations supported these regulations, which some view as an "ecological façade" that limits traditional use. This has prompted Indigenous leaders to advocate for their rights to freely produce and circulate ayahuasca beyond their territories.
Abstract
This chapter analyzes the environmental legislation on the use of ayahuasca in Brazil and its implications for Indigenous peoples. Although the fir...
Rapid Detection and Quantification of Hallucinogenic Salvinorin A in Commercial Salvia divinorum Products by DART-HRMS.
ACS omega – January 10, 2023
Summary
Enhanced Salvia products contain dramatically higher levels of the psychoactive compound salvinorin A than raw leaves, prompting the development of a swift method to identify and measure this substance. A novel approach using direct analysis mass spectrometry successfully bypassed lengthy sample preparation. This method rapidly screened plant material and accurately quantified salvinorin A. Raw Salvia leaves averaged 1.54 mg/g, while enhanced extracts contained 13.0 to 53.2 mg/g, revealing potent concentrations. This rapid, direct analysis offers a powerful tool for assessing psychoactive plant materials.
Abstract
In recent years, national laboratories have identified several plant-derived materials as concerns to public health because of their psychoactive e...
Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder
Neuropharmacology – January 06, 2023
Summary
Current anti-anxiety agents offer only temporary relief for prevalent psychiatric disorders like Anxiety and Panic disorder. A promising shift in Medicine and Psychiatry is underway. Clinical neuroscience and Neuropsychopharmacology are now developing anti-anxiety agents targeting diverse neurochemical systems, including monoamines (like those influenced by Psychedelics and Drug Studies), GABA, glutamate, and Nicotinic Acetylcholine Receptors. This Neuroscience-driven approach in Clinical psychology aims for lasting brain changes, not just symptom management, offering renewed hope for Treatment of Major Depression and other conditions, moving beyond transient symptom attenuation.
Abstract
Psychiatric disorders associated with psychological trauma, stress and anxiety are a highly prevalent and increasing cause of morbidity worldwide. ...
Use of psychoactive substances by goods carriage drivers associated with Kerala, India.
Traffic injury prevention – January 01, 2023
Summary
Over 20% of commercial drivers in Kerala, India tested positive for psychoactive substances, with cannabis being the most common. Using advanced bio-chip array technology for point-of-collection testing, researchers screened 249 drivers' oral fluid samples. Longer-distance drivers showed higher substance use rates. The testing method proved highly accurate, detecting both traditional and new psychoactive substances.
Abstract
This study aimed to measure the prevalence of drugs of abuse (DOA) among the goods carriage drivers associated with the southern State of India, Ke...
Predictors Of Hallucinogen Persisting Perception Disorder Symptoms, Delusional Ideation And Magical Thinking Following Naturalistic Psychedelic Use
OpenAlex – November 15, 2022
Summary
Compellingly, delusional ideation significantly reduced four weeks after a naturalistic psychedelic experience, despite a slight baseline correlation with lifetime use. Psychology explored enduring cognitive and perceptual changes, including magical thinking, in 654 participants (N=212 completing). Approximately a third (32.7%) reported HPPD-like symptoms, like intensified colors, but only 2.94% found them distressing. Using logistic regression for exploratory research, predictors for these Psychedelics and Drug Studies-related effects included younger age and female gender, offering insights for clinical psychology and psychiatry.
Abstract
OBJECTIVE: Psychedelics have over recent years been subject to a fast-paced growth in scientific research, clinical applications, commercial invest...
Psychedelic VR Experience: An Exploratory Study on Cosmic Flow
OpenAlex – November 09, 2022
Summary
Virtual reality offers a unique avenue for exploring altered states of consciousness. An exploratory research study with six participants investigated the user experience design of a psychedelic VR application. This Human-Computer Interaction and applied psychology effort revealed themes like introspection. Seven design considerations emerged for future virtual reality experiences, including non-invasive multi-sensory modalities and the effects of priming, relevant to agriculture, guiding computer science in Psychedelics and Drug Studies.
Abstract
Virtual environments are emerging as a tool for providing psychede-lic experiences due to the increasing interest in altered states of consciousnes...
Use of snuff and its main constituents for religious purposes in an alternative community with shamanic practices in the south of Brazil
Journal of Psychedelic Studies – September 21, 2022
Summary
Snuff, traditionally sacred in Indigenous cultures, has been commercialized, losing its medicinal and spiritual significance. This review highlights the diverse use of snuff across various American communities, emphasizing Erythroxylum coca and other plants integral to shamanism. In a Brazilian community study, it was noted that recreational snuff often lacks the therapeutic properties found in traditional formulations, which include local plants for spiritual communication. Understanding these differences is crucial, as they impact health and cultural practices associated with this complex ethnobotanical heritage.
Abstract
Abstract Snuff is a fine aromatic powder composed of dried and thin leaves combined with tobacco, roots, peels, and seeds. Its use for indigenous r...
Evaluation of the In Vitro Wound-Healing Potential of Ayahuasca.
Molecules (Basel, Switzerland) – September 06, 2022
Summary
Ancient Amazonian medicine shows promise for modern wound healing. Scientists found that ayahuasca plant mixtures stimulate skin cell regeneration without toxic effects. Lab tests using advanced techniques like HPLC-DAD showed the healing compounds stay in the skin's outer layer, promoting repair without entering deeper tissues. This suggests potential for safe, natural wound treatments.
Abstract
Ayahuasca is an Amazonian drink, which contains β-carboline alkaloids and N,N-dimethyltryptamine. The aim of this study was to evaluate the healing...